Proactive Research analyst Emma Ulker says US partnering discussions at Shield Therapeutics () are progressing and it's a key factor given that the US represents around 70% of the US$3bn global iron replacement market.
Ulker adds that the balance sheet was recently bolstered by an US$11.4mln milestone payment from China partner ASK Pharm, providing liquidity in the months ahead to negotiate potential uncertainty owing to the coronavirus crisis.
Click here to read Emma Ulker's latest research on Shield Therapeutics
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE